

Jasbir Sagoo, Ph.D.
Direct Line: 617-439-2997
Fax: 617-310-9994
E-mail: js@nutter.com

1619
RECEIVED
MAR 14 2007
TECH CENTER 1600/2001

#7
February 27, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/997,423
**EXPRESSION ANALYSIS OF FKBP NUCLEIC ACIDS AND POLYPEPTIDES
USEFUL IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER**
Applicant: Kimberly A. Gillis, Ph.D., et al
Docket No: 102729-12

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO-1449, Sixty-five (65) references cited therein;
3. Associate Power of Attorney; and
4. Return postcard.

Please charge any additional fee to our Deposit Account No. 141449.

Certificate of First Class Mailing (37 CFR 1.8(a))


I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231 on:

February 27, 2002

Date

Jasbir Sagoo, Registration No. P-51177

Respectfully submitted,


Jasbir Sagoo
Reg. No: P-51177
Nutter, McClennen & Fish, LLP
One International Place
Boston, MA 02110-2699
Agent For Applicants

1081936.1

Nutter McClennen & Fish LLP ■ Attorneys at Law

One International Place ■ Boston, MA 02110-2699 ■ 617-439-2000 ■ Fax: 617-310-9000 ■ www.nutter.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

Applicant : Kimberly A. Gillis, Ph.D., et al.
Application No. : 09/997,423
Filed : November 28, 2001
Entitled : EXPRESSION ANALYSIS OF FKBP
NUCLEIC ACIDS AND
POLYPEPTIDES USEFUL IN THE
DIAGNOSIS AND TREATMENT OF
PROSTATE CANCER
Docket No. : 102729-12

Group Art Unit: 1619
Examiner: Not Yet Assigned

<u>Certificate of Mailing (37 C.F.R. 1.8(a))</u>		
I hereby certify that this correspondence is being deposited with the United States Postal Service Post Office as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.		
February 27, 2002	By:	
Date of Signature and Mail Deposit		Jasbir Sagoo Reg. No: P-51177

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:


Applicant hereby cites for the record in this application the enclosed documents listed on the attached copy of PTO Form 1449. The enclosed Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. Accordingly, Applicant believes that no fee or certification is required.

The Assistant Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 141449.

Respectfully submitted,

NUTTER, MCCLENNEN & FISH, LLP

Date: February 27, 2002



Jasbir Sagoo
Reg. No. P-51177
Agent for Applicants

One International Place
Boston, MA 02110-2699
Tel: (617)439-2994
Fax: (617)310-9994

1081937.1



Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	09/997,423		
		Filing Date	November 28, 2001		
		First Named Inventor	Kimberly A. Gillis, Ph.D., et al.		
		Art Unit	1619		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	3	Attorney Docket Number	102729-12

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	5,030,559	07-09-1991	Nicolson et al.	
	AB	5,118,611	06-02-1992	Smith et al.	
	AC	5,362,718	11-08-1994	Skotnicki et al.	
	AD	5,629,007	05-13-1997	Audia et al.	
	AE	5,635,197	06-03-1997	Audia et al.	
	AF	5,801,197	09-01-1998	Steiner et al.	
	AG	5,674,682	10-07-1997	Croce et al.	
	AH	5,688,658	11-18-1997	Diamandis	
	AI	5,723,302	03-03-1998	Diamandis	
	AJ	5,763,202	06-09-1998	Horoszewicz	
	AK	5,843,994	12-01-1998	Samid	
	AL	5,854,206	12-29-1998	Twardzik et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 97/08318	03-06-1997	Corixa Corporation		
	BB	WO 97/33909	09-18-1997	Corixa Corporation		
	BC	WO 98/37093	08-27-1998	Corixa Corporation		
	BD	WO 98/37418	08-27-1998	Corixa Corporation		
	BE	WO 99/18210	04-15-1999	Corixa Corporation		
	BF	WO 99/37811	07-29-1999	UROCOR, Inc.		
	BG	WO 00/04149	01-27-2000	Corixa Corporation		
	BH	WO 00/14234	03-16-2000	UROCOR, Inc.		
	BI	WO 00/18961	04-06-2000	Millennium Pharmaceuticals, Inc.		
	BJ	EP 0 648 126 B1	02-02-2000	Procyon Biopharma, Inc.		
	BK	EP 0 698 215 B1	07-15-1998	Nordion International, Inc.		
	BL	EP 0 939 084 A1	09-01-1999	Rao, Ramanath B.		
	BM	EP 0 974 652 A1	01-26-2000	Banyu Pharmaceutical Co., Ltd.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Cleutjens, et al., "Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter," <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 11, March 15, 1996, pp 6379-6388	
	CB	Henttu, et al., "Androgens Up-Regulate the Human Prostate-Specific Antigen Messenger Ribonucleic Acid (mRNA), but Down-Regulate the Prostatic Acid Phosphatase mRNA in the LNCaP Cell Line," <i>Endocrinology</i> , Vol. 130, No. 2, 1992, pp 772	

TECH CENTER 1600/2900

MAR 14 2002

RECEIVED



TECH CENTER 1600/2900
MAR 14 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/997,423
		Filing Date	November 28, 2001
		First Named Inventor	Kimberly A. Gillis, Ph.D., et al.
		Group Art Unit	1619
		Examiner Name	Not Yet Assigned
Sheet	2	of	3
		Attorney Docket Number	102729-12

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AM	5,856,112	01-05-1999	Marley et al.	
	AN	5,859,031	01-12-1999	Hamilton et al.	
	AO	5,861,248	01-19-1999	Russell et al.	
	AP	5,882,864	03-16-1999	An et al.	
	AQ	5,912,253	06-15-1999	Cottens et al.	
	AR	5,939,258	08-17-1999	Croce et al.	
	AS	5,945,522	08-31-1999	Cohen et al.	
	AT	5,968,802	10-19-1999	Wang et al.	
	AU	5,972,615	10-26-1999	An et al.	
	AV	5,976,794	11-02-1999	Katz et al.	
	AW	5,976,838	11-02-1999	Jacobs et al.	
	AX	5,985,890	11-16-1999	Cottens et al.	
	AY	6,011,018	01-04-2000	Crabtree et al.	
	AZ	6,025,137	02-15-2000	Shyjan	
	AAA	6,028,174	02-22-2000	Ullrich et al.	
	AAB	6,034,218	03-07-2000	Reed et al.	
	AAC	6,051,230	04-18-2000	Thorpe et al.	
	AAD	6,054,265	04-25-2000	Barney et al.	
	AAE	6,166,011	12-26-2000	Wythes et al.	
	AAF	6,200,985 B1	03-13-2001	Cottens et al.	
	AAG	6,251,932 B1	06-26-2001	Reichelt et al.	
	AAH	6,252,058 B1	06-26-2001	Thompson	
	AAI	6,261,535 B1	07-17-2001	Thorpe et al.	
	AAJ	6,261,766 B1	07-17-2001	Diamandis	
	AAK	6,313,264 B1	11-06-2001	Caggiano et al.	
	AAL	6,319,891 B1	11-20-2001	Sontheimer et al.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CC	Horoszewicz, et al., "LNCaP Model of Human Prostatic Carcinoma", <i>Cancer Research</i> , Vol 43, April 1983, pp 1809-1818	
	CD	Kokontis, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation", <i>Cancer Research</i> , Vol. 54, March 15, 1992, pp 1566-1573	
	CE	Murtha, et al., "Androgen Induction of a Human Prostate-Specific Kallikrein, hKLK2: Characterization of an Androgen Response Element in the 5' Promoter Region of the Gene", <i>Biochemistry</i> , Vol. 32, 1993, pp 6459-6464	
	CF	Schuurmans, et al., "Regulation Of Growth Of LNCaP Human Prostate Tumor Cells By Growth Factors And Steroid Hormones," <i>J. Steroid Biochem. Molec. Biol.</i> , Vol. 40, No. 1-3, 1991, pp 193-197	
	CG	Silverstein et al., "Different Regions of the Immunophilin FKBP52 Determine Its Association With the Glucocorticoid Receptor, hsp90, and Cytoplasmic Dynein," <i>Journal of Biological Chemistry</i> , Vol. 274, No. 52, Dec. 24, 1999, pp 36980-36986	



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/997,423
		Filing Date	November 28, 2001
		First Named Inventor	Kimberly A. Gillis, Ph.D., et al.
		Group Art Unit	1619
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	102729-12
Sheet	3	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CH	Smith et al., "FKPB54, a Novel FK506-Binding Protein in Avian Progesterone Receptor Complexes and HeLa Extracts," <i>Journal of Biological Chemistry</i> , Vol. 268, No. 32, Nov. 15, 1993, pp 24270-24273	
	CI	Swinnen, et al., "Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP," <i>Molecular and Cellular Endocrinology</i> , Vol. 104, 1994, pp 153-162	
	CJ	Swinnen, et al., "Androgens Markedly Stimulate the Accumulation of Neutral Lipids in the Human Prostatic Adenocarcinoma Cell Line LNCaP," <i>Endocrinology</i> , Vol. 137, No. 10, 1996, pp 4468-4474	
	CK	Tamayo, et al., "Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 96, March 1999, pp 2907-2912	
	CL	Ulrix et al., "Androgens Down-Regulate the Expression of the Human Homologue of Paternally Expressed Gene-3 in the Prostatic Adenocarcinoma Cell Line LNCaP," <i>Molecular and Cellular Endocrinology</i> , Vol. 155, 1999, pp 69-76	
	CM	Ward et al., "Expression of the Estrogen Receptor-Associate Immunophilins, Cyclophilin 40 and FKPB52, in Breast Cancer," <i>Breast Cancer Research and Treatment</i> , Vol. 58, 1999, pp 267-280	
	CN	Yang et al., "Differential Expression and Androgen Regulation of the Human Selenium-Binding Protein Gene hSP56 in Prostate Cancer Cells," <i>Cancer Research</i> , Vol. 58, July 15, 1998, pp 3150-3153	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.